TABLE 3.
Outcomes of representative clinical trials of trabectedin in nonspecific STSs.
| Drugs and dosages | Years of report | Study types | Setting | Number of patients | Outcomes | References | ||
|---|---|---|---|---|---|---|---|---|
| ORR | M-PFS (months) | M-OS (months) | ||||||
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2022 | Phase IV trial | ≥2 line | 128 | 11.7% | 5.2 | 15.2 | Grunwald et al. (2022) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2021 | Phase III trial | ≥2 line | 52 | 13.7% | 3.1 | 13.6 | Le Cesne et al. (2021) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2020 | Phase II trial | First-line | 24 | - | 4 | 12 | Grosso et al. (2020) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2017 | Phase IV trial | No line | 218 | 26.6% | 5.9 | 21.3 | Buonadonna et al. (2017) |
| Trabectedin 1.2 mg/m2/24 h–infusion/3w | 2015 | Phase II trial | ≥2 line for translocation-related sarcomas | 37 | 8% | 5.6 | - | Kawai et al. (2015) |
| Trabectedin 1.3 mg/m2/3 h–infusion/3w | 2015 | Phase II trial | First-line | 47 | 14.8% | 2.8 | - | Bui-Nguyen et al. (2015) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2015 | Phase II trial | First-line | 43 | 4.7% | 3.1 | - | Bui-Nguyen et al. (2015) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2014 | Phase III trial | First-line for translocation-related sarcomas | 61 | 5.9% | 16.1 | 38.9 | Blay et al. (2014) |
| Trabectedin 1.5 mg/m2/24 h–infusion/3w | 2005 | Phase II trial | ≥2 line | 99 | 8.1% | 3.5 | 9.2 | Le Cesne et al. (2005) |
| Trabectedin 1.1 mg/m2/d1/3w plus doxorubicin 60 mg/m2/d1/3w | 2016 | Phase II trial | First-Line | 54 | 17% | 5.7 | 13.3 | Martin-Broto et al. (2016) |
STSs, soft tissue sarcomas; ORR, objective response rate; M-PFS, median progression-free survival; M-OS, median overall survival.